{"id":49100,"date":"2019-02-19T11:53:18","date_gmt":"2019-02-19T10:53:18","guid":{"rendered":"https:\/\/www.cfmot.de\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/"},"modified":"2019-02-19T11:53:20","modified_gmt":"2019-02-19T10:53:20","slug":"beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs","status":"publish","type":"post","link":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/","title":{"rendered":"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"49100\" class=\"elementor elementor-49100 elementor-49097\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5447990 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5447990\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c8a71c2\" data-id=\"c8a71c2\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-711a4bd elementor-widget elementor-widget-text-editor\" data-id=\"711a4bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"p1\"><span class=\"s1\">beta-Amanitin is an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, but not RNA polymerase I or bacterial RNA polymerase. It inhibits mammalian protein synthesis. These properties make it interesting as a new potential drug for ADC research. \u03b1-Amanitin is already known as effective payload for ADCs. beta-Amanitin has a comparable biological activity but in addition it has a carboxy group, suitable for coupling reactions.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">ADC technology offers a wide potential for the future and Cfm Oskar Tropitzsch GmbH supplies besides beta-Amanitin many other payloads for antibody drug conjugation (ADC).<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f631ca3 elementor-align-center btn elementor-widget elementor-widget-button\" data-id=\"f631ca3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Go to product<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>beta-Amanitin is an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, but not RNA polymerase I or bacterial RNA polymerase. It inhibits mammalian protein synthesis. These properties make it interesting as a new potential drug for ADC research. \u03b1-Amanitin is already known as effective payload for ADCs. beta-Amanitin has a comparable biological activity [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[134,48],"tags":[],"class_list":["post-49100","post","type-post","status-publish","format-standard","hentry","category-adcs-en","category-blog-en-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs) - Cfm Oskar Tropitzsch GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs) - Cfm Oskar Tropitzsch GmbH\" \/>\n<meta property=\"og:description\" content=\"beta-Amanitin is an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, but not RNA polymerase I or bacterial RNA polymerase. It inhibits mammalian protein synthesis. These properties make it interesting as a new potential drug for ADC research. \u03b1-Amanitin is already known as effective payload for ADCs. beta-Amanitin has a comparable biological activity [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/\" \/>\n<meta property=\"og:site_name\" content=\"Cfm Oskar Tropitzsch GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-19T10:53:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-19T10:53:20+00:00\" \/>\n<meta name=\"author\" content=\"4cfabian\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"4cfabian\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/\"},\"author\":{\"name\":\"4cfabian\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/cfda3575aaaf36e88c60c988a3a319e8\"},\"headline\":\"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs)\",\"datePublished\":\"2019-02-19T10:53:18+00:00\",\"dateModified\":\"2019-02-19T10:53:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/\"},\"wordCount\":104,\"articleSection\":[\"ADCs\",\"Blog\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/\",\"name\":\"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs) - Cfm Oskar Tropitzsch GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#website\"},\"datePublished\":\"2019-02-19T10:53:18+00:00\",\"dateModified\":\"2019-02-19T10:53:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/cfda3575aaaf36e88c60c988a3a319e8\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/\",\"name\":\"Cfm Oskar Tropitzsch GmbH\",\"description\":\"Chemikalien, Feinchemikalien, Metallverbindungen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/cfda3575aaaf36e88c60c988a3a319e8\",\"name\":\"4cfabian\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/author\\\/4cfabian\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs) - Cfm Oskar Tropitzsch GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/","og_locale":"en_US","og_type":"article","og_title":"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs) - Cfm Oskar Tropitzsch GmbH","og_description":"beta-Amanitin is an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, but not RNA polymerase I or bacterial RNA polymerase. It inhibits mammalian protein synthesis. These properties make it interesting as a new potential drug for ADC research. \u03b1-Amanitin is already known as effective payload for ADCs. beta-Amanitin has a comparable biological activity [&hellip;]","og_url":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/","og_site_name":"Cfm Oskar Tropitzsch GmbH","article_published_time":"2019-02-19T10:53:18+00:00","article_modified_time":"2019-02-19T10:53:20+00:00","author":"4cfabian","twitter_card":"summary_large_image","twitter_misc":{"Written by":"4cfabian"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/#article","isPartOf":{"@id":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/"},"author":{"name":"4cfabian","@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/cfda3575aaaf36e88c60c988a3a319e8"},"headline":"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs)","datePublished":"2019-02-19T10:53:18+00:00","dateModified":"2019-02-19T10:53:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/"},"wordCount":104,"articleSection":["ADCs","Blog"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/","url":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/","name":"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs) - Cfm Oskar Tropitzsch GmbH","isPartOf":{"@id":"https:\/\/www.cfmot.de\/en\/#website"},"datePublished":"2019-02-19T10:53:18+00:00","dateModified":"2019-02-19T10:53:20+00:00","author":{"@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/cfda3575aaaf36e88c60c988a3a319e8"},"breadcrumb":{"@id":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cfmot.de\/en\/beta-amanitin-a-potential-payload-for-antibody-drug-conjugates-adcs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cfmot.de\/en\/"},{"@type":"ListItem","position":2,"name":"Beta-Amanitin \u2013 a potential payload for antibody drug conjugates (ADCs)"}]},{"@type":"WebSite","@id":"https:\/\/www.cfmot.de\/en\/#website","url":"https:\/\/www.cfmot.de\/en\/","name":"Cfm Oskar Tropitzsch GmbH","description":"Chemikalien, Feinchemikalien, Metallverbindungen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cfmot.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/cfda3575aaaf36e88c60c988a3a319e8","name":"4cfabian","url":"https:\/\/www.cfmot.de\/en\/author\/4cfabian\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/49100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/comments?post=49100"}],"version-history":[{"count":1,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/49100\/revisions"}],"predecessor-version":[{"id":49101,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/49100\/revisions\/49101"}],"wp:attachment":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/media?parent=49100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/categories?post=49100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/tags?post=49100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}